Table 1 Pre-treatment characteristics of 59 patients with EGFR mutant NSCLC treated with first line EGFR-TKIs
From: miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
Clinical characteristics | Patient number (%) |
|---|---|
Sex | |
 Male | 36 (61.0) |
 Female | 23 (39.0) |
Age | |
 < 60 | 40 (67.8) |
 ≥ 60 | 19 (32.2) |
Smoking status | |
 Never smoked | 17 (28.8) |
 Former smoker | 28 (47.5) |
 Current smoker | 14 (23.7) |
ECOG*performance status | |
 0 | 21 (35.6) |
 1 | 32 (54.2) |
 2 | 4 (6.8) |
 3 | 2 (3.4) |
Disease stage | |
 IIIB | 18 (30.5) |
 IV | 41 (69.5) |
Brain metastasis | |
 - | 51 (86.4) |
 + | 8 (13.6) |
Bone metastasis | |
 - | 34 (57.6) |
 + | 25 (42.4) |
Type of EGFR mutation | |
 Exon 19 deletion | 46 (78.0) |
 L858R | 12 (20.3) |
 Other | 1 (1.7) |
EGFR-TKI type as first-line therapy | |
 Gefitinib | 26 (44.1) |
 Erlotinib | 31 (52.5) |
 Afatinib | 2 (3.4) |